公开(公告)号：US20240245711A1

公开(公告)日：2024-07-25

申请号：US18550724

申请日：2022-03-17

Applicant: Sage Therapeutics, Inc.

Inventor： Robert Alfonso Lasser ,  James Doherty ,  Jeffrey Martin Jonas ,  Stephen Jay Kanes ,  Handan Gunduz-Bruce ,  Joi Lisa Dunbar ,  Bambang Senoaji Adiwijaya

IPC: A61K31/58 ,  A61P25/24

CPC classification number: A61K31/58 ,  A61P25/24

Abstract: The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.

公开(公告)号：US20240216395A1

公开(公告)日：2024-07-04

申请号：US18557691

申请日：2022-04-29

Applicant: Sage Therapeutics, Inc.

Inventor： Robert Alfonso Lasser ,  James Doherty ,  Jeffrey Martin Jonas ,  Stephen Jay Kanes ,  Handan Gunduz-Bruce ,  Helen Anne Colquhoun ,  Ryan Arnold ,  Vijayveer Bonthapally ,  Joi Lisa Dunbar ,  Bambang Senoaji Adiwijaya

IPC: A61K31/58 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

CPC classification number: A61K31/58 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

Abstract: The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.